What is SAGA Diagnostics?
SAGA Diagnostics AB operates at the intersection of precision medicine and molecular oncology. The company specializes in the development of highly sensitive genetic testing platforms designed for both tissue biopsies and liquid biopsies. By leveraging advanced genomic analysis, SAGA provides clinicians with actionable insights for disease monitoring, effectively bridging the gap between traditional pathology and real-time molecular surveillance. Their market position is defined by a commitment to high-precision diagnostics that facilitate personalized treatment pathways for cancer patients, a sector currently experiencing rapid technological maturation and increased demand for non-invasive screening solutions.
How much funding has SAGA Diagnostics raised?
SAGA Diagnostics has raised a total of $12.5M across 1 funding round:
Series A
$12.5M
Series A (2021): $12.5M with participation from Hadean Ventures and Segulah Medical Acceleration
Key Investors in SAGA Diagnostics
Hadean Ventures
A European life science venture capital firm that invests in early-stage and growth-stage companies developing innovative medical technologies and therapeutics.
Segulah Medical Acceleration
A specialized investment firm focused on accelerating the growth of medical technology companies with high potential for clinical impact and market scalability.
What's next for SAGA Diagnostics?
Following this major strategic investment, SAGA Diagnostics is expected to scale its operational infrastructure and expand its clinical validation studies. The capital will likely be deployed to enhance the sensitivity of their liquid biopsy assays, ensuring broader adoption within hospital networks and diagnostic laboratories. As the company transitions from a development-focused entity to a commercial-scale enterprise, the focus will shift toward regulatory milestones and strategic partnerships with pharmaceutical firms. This growth trajectory suggests a long-term objective of establishing their diagnostic suite as a standard-of-care tool in global oncology, ultimately improving patient outcomes through early detection and longitudinal disease tracking.
See full SAGA Diagnostics company page
